SCHEMBL5701142

SCHEMBL5701142

CCCCCCCCNCCOc1ccc2ccccc2c1

nearest known ligand 0.58

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.58
KMT2A Q03164 1/20 0.57
DRD2 P14416 9/20 0.54
DRD4 P21917 9/20 0.54
DRD3 P35462 7/20 0.54
ESR1 P03372 7/20 0.52
KDM4E B2RXH2 1/20 0.50
MAPK1 P28482 1/20 0.50
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5701183 1.00 PPARG (0.58) PPARGKMT2ADRD2DRD4DRD3
SCHEMBL5701126 0.98 KMT2A (0.58) PPARGKMT2ADRD2DRD4DRD3
SCHEMBL5701254 0.98 KMT2A (0.58) PPARGKMT2ADRD2DRD4DRD3
SCHEMBL5701273 0.95 KMT2A (0.55) PPARGKMT2AKDM4EMAPK1TDP1
SCHEMBL4786117 0.92 KMT2A (0.61) PPARGKMT2ADRD2DRD4DRD3
SCHEMBL5701188 0.91 KMT2A (0.60) PPARGKMT2ADRD2DRD4DRD3
SCHEMBL4738576 0.89 PPARG (0.59) PPARGKMT2ADRD2DRD4DRD3
SCHEMBL5701216 0.88 PPARG (0.54) PPARGKMT2ADRD2DRD4DRD3
SCHEMBL10587825 0.86 KDM4E (0.61) DRD3KDM4EMAPK1TDP1
SCHEMBL11077065 0.86 KDM4E (0.61) DRD3KDM4EMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682484-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-26 EP claimed
US-7081465-B2 Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-25 US claimed
WO-2005042465-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-05-12 WO claimed
EP-1682484-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-26 EP disclosed
US-7081465-B2 Alpha-substituted naphthyloxy omega-substituted alky/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-07-25 US disclosed
WO-2005042465-A1 OMEGA-SUBSTITUTED-NAPHTHYLOXYALKLAMINO DERIVATIVES AS ANTIHYPERGLYCEMIC AGENTS AND PREPARATION COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2005-05-12 WO disclosed
US-20040192688-A1 Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192688-A1 Alpha-substituted naphthyloxy omega-substituted alkyl/aryl amino-substituted alkane derivatives as agent for treatment or prophylaxis of diabetes and related metabolic disorders APOB, LIPC, FABP3 PPARG 102/4885KMT2A 2747/4885DRD2 720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.